ABILITYPHARMA
AbilityPharma is a clinical stage biopharmaceutical company focused on autophagy to treat cancer
PIPELINE
ABTL0812, first-in-class, is currently in phase 2 clinical trials in lung cancer and endometrial cancer patients in Spain and France
SCIENCE
AbilityPharma investigates cancer drugs inducing cytotoxic autophagy selectively in cancer cells
AbilityPharma is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
Media Center
28.12.2020
The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020
The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
29.12.2020
The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million + info
